CD40- and CD95-specific antibody single chain-Baff fusion proteins display BaffR-, TACI- and BCMA-restricted agonism.
Antibodies, Monoclonal
/ genetics
B-Cell Activating Factor
/ genetics
B-Cell Activation Factor Receptor
/ agonists
B-Cell Maturation Antigen
/ agonists
CD40 Antigens
/ immunology
HEK293 Cells
Humans
Immunoglobulin Fab Fragments
/ genetics
Jurkat Cells
Recombinant Fusion Proteins
/ genetics
Transmembrane Activator and CAML Interactor Protein
/ agonists
fas Receptor
/ immunology
Antibody fusion protein
CD40
CD95
TNFRSF
bifunctional
Journal
mAbs
ISSN: 1942-0870
Titre abrégé: MAbs
Pays: United States
ID NLM: 101479829
Informations de publication
Date de publication:
Historique:
entrez:
26
8
2020
pubmed:
26
8
2020
medline:
6
7
2021
Statut:
ppublish
Résumé
Antibodies that target a clinically relevant group of receptors within the tumor necrosis factor receptor superfamily (TNFRSF), including CD40 and CD95 (Fas/Apo-1), also require binding to Fc gamma receptors (FcγRs) to elicit a strong agonistic activity. This FcγR dependency largely relies on the mere cellular anchoring through the antibody's Fc domain and does not involve the engagement of FcγR signaling. The aim of this study was to elicit agonistic activity from αCD40 and αCD95 antibodies in a myeloma cell anchoring-controlled FcγR-independent manner. For this purpose, various antibody variants (IgG1, IgG1
Identifiants
pubmed: 32840410
doi: 10.1080/19420862.2020.1807721
pmc: PMC7531569
doi:
Substances chimiques
Antibodies, Monoclonal
0
B-Cell Activating Factor
0
B-Cell Activation Factor Receptor
0
B-Cell Maturation Antigen
0
CD40 Antigens
0
FAS protein, human
0
Immunoglobulin Fab Fragments
0
Recombinant Fusion Proteins
0
TNFRSF13B protein, human
0
TNFRSF13C protein, human
0
TNFRSF17 protein, human
0
TNFSF13B protein, human
0
Transmembrane Activator and CAML Interactor Protein
0
fas Receptor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Video-Audio Media
Langues
eng
Sous-ensembles de citation
IM
Pagination
1807721Références
J Exp Med. 1995 Nov 1;182(5):1223-30
pubmed: 7595193
Cancer Res. 2000 Jun 15;60(12):3225-31
pubmed: 10866315
Haematologica. 2010 May;95(5):845-8
pubmed: 20133895
ESMO Open. 2019 Jun 12;4(Suppl 3):e000510
pubmed: 31275618
Mol Ther. 2015 Apr;23(4):769-78
pubmed: 25582824
Blood. 2018 Jan 4;131(1):49-57
pubmed: 29118009
Haematologica. 2007 Jun;92(6):803-11
pubmed: 17550853
Science. 2011 Aug 19;333(6045):1030-4
pubmed: 21852502
Cell. 2001 Feb 23;104(4):487-501
pubmed: 11239407
Cell Death Differ. 2012 Jul;19(7):1187-95
pubmed: 22261618
Nat Rev Immunol. 2009 Jul;9(7):491-502
pubmed: 19521398
Cancer Res. 2005 Jul 1;65(13):5898-906
pubmed: 15994968
Eur J Immunol. 1988 Mar;18(3):451-7
pubmed: 2451615
Expert Rev Hematol. 2018 May;11(5):423-435
pubmed: 29582696
J Immunol. 2009 Aug 1;183(3):1851-61
pubmed: 19596991
J Immunol. 2003 Jul 15;171(2):562-8
pubmed: 12847219
Cancer Cell. 2019 Mar 18;35(3):473-488.e6
pubmed: 30889381
Curr Opin Immunol. 2013 Apr;25(2):230-7
pubmed: 23414607
Expert Opin Ther Targets. 2019 Apr;23(4):295-307
pubmed: 30856027
Eur J Immunol. 2000 Mar;30(3):725-31
pubmed: 10741386
J Biol Chem. 2003 Feb 28;278(9):7553-7
pubmed: 12477718
Br J Haematol. 2012 Oct;159(1):58-66
pubmed: 22861192
Blood. 2016 Sep 29;128(13):1688-700
pubmed: 27412889
Trends Mol Med. 2013 Jun;19(6):329-35
pubmed: 23540716
MAbs. 2017 Apr;9(3):506-520
pubmed: 28095113
Immunity. 2018 Nov 20;49(5):958-970.e7
pubmed: 30446386
Cancer Res. 2005 Sep 15;65(18):8331-8
pubmed: 16166310
Blood. 2005 Feb 15;105(4):1396-404
pubmed: 15486063
Expert Opin Biol Ther. 2019 Nov;19(11):1143-1156
pubmed: 31277554
J Clin Invest. 2019 Mar 21;129(6):2210-2221
pubmed: 30896447
Cancer Cell. 2016 Jun 13;29(6):820-831
pubmed: 27265505
Proc Natl Acad Sci U S A. 2013 Nov 26;110(48):19501-6
pubmed: 24218606
Clin Cancer Res. 2013 Apr 15;19(8):2048-60
pubmed: 23344265
J Clin Oncol. 2018 Aug 1;36(22):2267-2280
pubmed: 29812997
Annu Rev Med. 2020 Jan 27;71:47-58
pubmed: 31412220
Nature. 1993 Aug 26;364(6440):806-9
pubmed: 7689176
Blood. 2004 Jan 15;103(2):689-94
pubmed: 14512299
Cell Death Differ. 2015 Nov;22(11):1727-41
pubmed: 26292758
Lancet Oncol. 2018 Dec;19(12):1641-1653
pubmed: 30442502
Nat Rev Cancer. 2017 May 24;17(6):352-366
pubmed: 28536452
J Biol Chem. 2016 Mar 4;291(10):5022-37
pubmed: 26721880
Front Immunol. 2018 Aug 10;9:1821
pubmed: 30147690
J Hematol Oncol. 2018 Dec 20;11(1):141
pubmed: 30572922
Blood. 2010 Oct 21;116(16):3004-12
pubmed: 20616215
Blood Cancer J. 2019 Mar 20;9(4):37
pubmed: 30894515